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INTRODUCING A NOVEL METHOD FOR GENETIC ANALYSIS OF  
AUTISM SPECTRUM DISORDER 
Sepideh Nouri, M.S. 
Supervisory Professor: Eric Boerwinkle, Ph.D. 
 
Autism is a spectrum of neurological disorders that is characterized by 
repetitive and stereotyped behaviors, lack of social skills in verbal and non-verbal 
communications, and intellectual disability. Recent statistics shows that 1 out of 
every 88 children in the US is affected by autism. 
In this thesis, I first review previous studies on genetic association 
analyses of autism spectrum disorder. A large number of these studies fall into 
two categories: Genome Wide Association Studies (GWAS) and sequencing 
studies. Although GWAS are able to identify multiple common risk variants 
associated with different diseases, these common variants explain only a small 
portion of disease occurrence. In the case of autism, GWAS has had only limited 
success in identification of common risk variants. Recent studies suggest that 
rare variants have an important role in causing this disorder. There are a number 
of sequence-based association studies that have analyzed the relationship of 
rare variants with autism.  
Chapter 2 of my thesis presents some of the most popular sequencing-
based rare variant association analysis methods along with their advantages and 
disadvantages. From previously published methods, the Weighted Sum Method 
(WSM) and Sequence Kernel Association Test (SKAT) are used to analyze the 
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autism disease sequencing data since they have some advantages over similar 
methods. A new method called the Single Variant Method (SVM) is introduced in 
section 2.4. This new method provides a better understanding of the data and 
identifies associated variants not found by the previous methods.  
In Chapter 3, the results of the analysis of the autism data using WSM, 
SKAT and SVM are presented and discussed. Although there is no gold 
standard, there is insightful information to be learned by applying multiple 
methods, including the novel SVM method proposed here. 
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Autism is a neurological disorder caused by chemical irregularities in the 
brain and nervous system [1]. The symptoms of autism and their severity vary 
considerably from one patient to another. Symptoms of this disorder include lack 
of social skills in verbal and non-verbal communications, intellectual disability, 
language difficulties and behavioral impairments [1]. Because of the range of 
symptoms across domains and among patients, the condition is best referred to 
as autism spectrum disorder. In order to diagnose this condition, the symptoms 
should be visible in the patient and usually they are detectable before age 3 [2]. 
According to the most recent statistics by the Centers for Disease Control 
and Prevention (CDC), 1 out of every 88 children in the U.S. is affected by autism 
[3]. Previous estimates of autism's prevalence were approximately 1 in every 110 
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U.S. children [3]. These data indicate that the prevalence of autism has 
increased during the past several years. Additionally, boys are 5 times more 
likely to be affected by autism than girls. The CDC estimates that one in 54 boys 
and one in 252 girls have autism [3]. 
Both genetic factors and environmental influences can be considered as 
risk factors for autism. However, genetics seems to have a more prominent role 
in the etiology of this disorder. Among the environmental risk factors, the MMR 
(measles, mumps, and rubella) vaccination deserves special mention. Singh and 
Jensen [4] showed that autistic children produce a significantly higher level of 
antibody in response to MMR vaccination compared to normal children. Other 
environmental risk factors that can be influential are advanced maternal age [5], 
alcohol consumption and smoking during the pregnancy, as well as having 
contact with specific substances like heavy metals and pesticides [5,6]. The 
importance of all of these environmental factors, as risk factors for autism, is 
controversial and further studies are required. 
1.2 Genetics of Autism- a review of the literature 
Genetics has a strong influence in the development of autism. This is 
based on a large number of family and twins studies that have been conducted 
[7-12]. 
Multiple studies consistently show that monozygotic (identical) twins have 
higher concordance of autism susceptibility compared with dizygotic (non-
identical) twins. Since the genetic make up of identical twins is almost 100% 
similar (compared to 50% in dizygotic twins), these results confirm the 
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importance of a genetic role in autism [7-11]. In a study of 277 twins (210 non- 
identical, 67 identical), where at least one of them was diagnosed with autism, 
the concordance of autism in identical twins was shown to be 2 to 5 times higher 
than the non-identical twins [7]. 
Since patients with autism demonstrate symptoms in a wide range of 
intensities, some studies adopt a rating system for patient evaluation. In another 
twin study, 45 twins (19 identical, 26 non-identical) were evaluated using a 
severity rating system [11]. This method enabled researchers to use quantitative 
approaches in their analysis. In this study a scale of 1-4 was used for rating the 
severity of the autism symptoms, where 1 indicates a child with no symptom and 
4 indicates one with very severe symptoms. Using this scoring system, Taniai et 
al. calculated a heritability of 0.73 for males and 0.87 for females. They also 
indicated that, if one of the twins has autism, the chance of the other twin having 
autism is about 3 fold higher in identical twins versus non-identical ones [11]. 
Additional studies have confirmed that the recurrence of autism or some 
kinds of symptoms in families and close relatives of autistic children is more 
frequent than in children without autism [12,13,14,15,16]. In a study of 664 
infants in which their older siblings had already been diagnosed with autism, the 
infants were followed for 3 years and 18.7% of them developed autism. 
Additionally, the recurrence risk doubled for children who had more than one 
affected sibling. Further, male siblings had three times higher risk of developing 
autism [12]. 
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In a study of 25 families with at least two autistic children, parents in each 
family as well as some close relatives such as grandparents and uncles were 
interviewed [14]. The results of this study showed that parents of autistic children 
have a significantly higher rate of exhibiting some kinds of autistic phenotypes 
themselves compared with the general population. Often other family members 
showed some of the symptoms of autism, such as social skills impairment or 
repetitive behavior [14]. 
Based on the above data, I hypothesize that genetics plays an important 
role in the development of autism, but the exact genetic model of autism is still 
unknown. A possible model may involve a specific combination of common 
variants with small effect and rare variants with large effect. 
Efforts to date to find susceptible genetic components of autism have not 
been very successful.  A number of linkage and candidate gene studies have 
pointed to possible susceptible genomic regions, such as those on chromosomes 
6q21, 6q27 and 20p13 [16,17]. Some of the genes that are frequently reported 
are RELN, GRIK2 and SHANK3 [18,19]. Although these genes show significant 
association with the disease, there are still some controversies about their role in 
this disorder [18,19]. 
1.2.1 GWAS and Sequencing Studies 
In recent years an important paradigm shift has occurred in the field of 
human genetics. Many new technologies have been developed that have 
significantly reduced the cost of DNA sequencing. Based on a report by the 
National Human Genome Research Institute of NIH, the cost of whole genome 
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sequencing (~3 billion base pairs) was about $100M in 2001, $10M in 2007, 
$100K in 2009, and $5K in 2012 [20]. This significant reduction in sequencing 
costs has fueled many new research and clinical programs focused on finding 
genes and single nucleotide polymorphisms (SNPs) associated with a multitude 
of diseases. In the case of autism research [21], many leading research 
institutions used this opportunity to find important genes responsible for autism 
by genotyping or sequencing the genomes of many individuals. These studies 
can be divided into two major categories. The first category is the genome wide 
association studies (GWAS), where a large number of common variants are 
examined to calculate their statistical association with autism. So far GWAS has 
had limited success in the identification of common risk variants of autism 
spectrum disorder [43]. In the second category, which is more recent and relies 
on DNA sequencing, rare variants are also included in the analysis. 
One of the important genes that were found in sequencing studies is 
SHANK3 [22-23]. SHANK3 codes for a protein that controls synaptic function. 
This protein is essential in the development of language and social skills. In 
addition to SHANK3, variants in NLGN3 and NLGN4X have also been identified 
in brothers with autism [24]. In another study [25], a strong association was found 
with the gene CNTNAP2, which encodes a protein in the nervous system that 
plays a role in interactions between the neurons and glia [26]. Miles et al [24] 
reported that the gene CNT4 has a strong association with autism and 
developmental delays. The protein encoded by CNT4 is a member of 
immunoglobulin superfamily and affects axons in the developing nervous system. 
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In [27], the association of NRCAM and autism has been studied. This study 
focused on 18 SNPs in 170 patients and 214 controls. It was found that 7 SNPs 
in this gene are significantly associated with autism. This gene is a member of 
immunoglobulin super family and is expressed in the central nervous system. 
The protein encoded by this gene controls neuron-neuron adhesion and 
directional signaling. In [28], mutations in the genes HOXA1 and HOXB1 were 
associated with autism. The encoded protein by these genes affects the 
placement of hindbrain segments along the anterior- posterior axis during 
development. 
Studying associations of rare variants with autism requires sequencing of 
a large number of individuals. Fortunately, recent progress in developing low-cost 
high-throughput sequencing technologies have made it possible to find rare 
variants associated with autism. In [29], the sequencing of genes involved in 
metabotropic glutamate-receptor (mGluR) signaling pathway revealed significant 
rare variants associated with autism. The mGluRs are glutamate receptors that 
affect various functions in the nervous system. They are involved in anxiety, 
learning, and memory. In [29], 290 patients and 300 controls were sequenced for 
18 candidate genes in mGluR pathway. Rare variants in genes TSC1, TSC2, and 
SHANK3 were detected that contribute to autism susceptibility. It was also found 
that rare variants in the gene HOMER1 that interacts with Shank3 have 
damaging effects in the mGluR pathway, which suggests that rare variant may be 
responsible for the autism disorders. 
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A recent study has pointed out the relationship between father’s age and 
risk of autism in the children [36]. This study was performed on 78 trios (mother, 
father and child) and consisted of 44 autistic children, 
21 schizophrenic children and   13 normal children. They showed that for every 
year increase in the father’s age at the time of conceiving the number of de 
novo mutations in his child increases by 2. Also, every 16.5 years increase in the 
age of fatherhood doubles the total number of de novo mutations in his child. 
This study showed a significant positive relationship between the father's age 
and the chance of having an autistic child [36]. A number of studies 
previously showed the importance of de novo mutations in the development of 
autism disease [37-39]. They also reported a number of significant de novo 
coding mutations. In the following genes: CHD8 [37,38], KATNAL2 [37], 
NTNG1, GRIN2B, LAMC3, SCN1A [38], and SCN2A [39]. 
1.3 Conclusion 
A large number of studies have been done so far to uncover the etiology 
of autism. These studies have shown that genetics has an important role in the 
development of autism and a number of genes have been found to be 
significantly associated with this disease. However, the complete genetic model 
of autism is not clear and more research is required to improve our 
understanding of the genetics of autism spectrum disorder.











Genome Wide Association Studies (GWAS) have been able to identify 
numerous common risk variants associated with different diseases. However, 
common variants detected by this method, have been able to explain only a 
small portion of disease occurrence. In the case of autism, as explained in the 
previous chapter, GWAS had limited success in the identification of common risk 
variants. The major problem is that methods used for analysis of common 
variants do not have sufficient power to analyze rare variants unless the sample 
sizes are very large (e.g. of the order of hundreds of thousands). 
To help solve this problem a number of techniques have been proposed. 
In this section, some of the most popular methods for identifying rare variant 
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associations along with their advantages and disadvantages are presented. 
These methods can be summarized into two main categories: burden test 
methods and regression methods. 
In burden test methods, instead of taking the effect of only one variant into 
account, we analyze the summed effects of a group of rare variants or a 
combination of rare and common variants.  The variants are usually grouped in 
an a priori biologically meaningful manner. For example, they belong to the same 
gene or participate in the same pathway. Two examples of burden tests are 
Combined and Multivariate Collapsing (CMC) and Weighted Sum Method 
(WSM). [30, 31] 
One of the challenging problems in achieving reliable results from burden 
tests is controlling for the effects of common variants, which can dominate the 
effects of rare variants.  To limit the impact of common variants on the results, 
CMC uses a frequency threshold to separate and eliminate common variants.  
Alternatively, WSM uses a weighting method to increase the weight of the rare 
variants while keeping the common variants in the analysis. This approach 
causes WSM to have an advantage over CMC because it does not eliminate the 
effects of the common variants entirely. In some cases, a combination of 
common variants and rare variants may play a significant role in causing disease. 
These cases may be completely missed by the CMC method. Further, in many 
examples, there is no solid reason for choosing a particular frequency threshold 
value. An arbitrary choice of the threshold value can negatively impact the results 
by eliminating important genes. [32] 
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One weakness of burden tests is their relative inability to adjust for the 
effect of covariates. Since burden tests use permutation for finding the 
association, they cannot readily adjust for covariates. Another weakness of 
burden tests is that they are computationally intensive. This is because they 
require a very large number of permutations to produce reliable results. This 
becomes a major challenge in the analysis of whole genome or exome sequence 
data. [32] 
Another category for analysis of rare variants is regression-based tests. 
The Sequence Kernel Association Test (SKAT) is a popular method that is based 
on regression. SKAT has some advantages over burden tests, such as it can 
accommodate covariates and it can be used for either continuous or discrete 
phenotypes [32]. SKAT also uses a weighting technique based on the minor 
allele frequency (MAF) to control how much to up-weight rare variants. Choosing 
the right weights can be challenging and different weights can lead to different 
results. 
From previously published methods, I chose WSM and SKAT to analyze 
the autism disease sequencing data available to me since they have some 
advantages over similar methods. Additionally, I have explored the autism data 
with a method that I will introduce in section 2.4. This new method, which is 
called Single Variant Method (SVM), provided a better understanding of the data 
and identified associated variants not identified by the previous methods. In the 
next section, I summarize the methods of WSM, SKAT, and SVM in more depth. 
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2.2 Weighted-Sum Method (WSM) 
The WSM compares the weighted count of mutations between cases and 
controls in a group of variants. The variants in a group can be related to a gene 
or a pathway. Each variant is denoted by a variable 𝐼𝑖 ∈    {0, 1, 2}, indicating zero, 
one, or two minor alleles in that locus. Variable 𝐼𝑖 is divided by a weight, called 
𝑤𝑖, which is basically the standard deviation of the number of mutations for that 
specific variant across all cases and controls. The calculation of 𝑤𝑖 is shown 
below [31]. 
𝑤𝑖 = 𝑛𝑖. 𝑞𝑖(1 − 𝑞𝑖) Eq. 1 
Where, 
𝑞𝑖 = 𝑚𝑖𝑈!!!𝑛𝑖𝑈!!   
𝑛𝑖: Total number of individuals (affected + unaffected)  
𝑛𝑖𝑈: Total number of unaffected individuals 
𝑚𝑖𝑈: Total number of alternate allele for variant 𝑖 
As a variant declines in frequency, its standard deviation (or 𝑤𝑖) becomes 
smaller and 𝐼𝑖
𝑤𝑖
 becomes larger. Next, I add 𝐼𝑖
𝑤𝑖
 for all 𝐿 variants in the group for 
each person and call it the score of individual 𝑗, which is denoted by 𝛾𝑗. 
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𝛾𝑗 =    𝐼𝑖𝑗𝑤𝑖𝐿𝑖!!   Eq. 2 
Then all individuals are ranked based on their score. The next step is to add the 
ranks of affected individuals and call it 𝑥. 
   𝑥 = 𝑟𝑎𝑛𝑘  (𝛾𝑗)𝑗∈𝐴   Eq. 3 
When affected individuals have significantly more mutations compared to 
controls the value of 𝑥 will be larger, due to the fact that cases have earned 
larger scores. To find a p-value to a specific contrast case and control 
assignments are permuted in a random fashion and then a new 𝑥 is calculated 
for each permutation. The permutation step is repeated as many times as 
necessary (1000-10000 repetition) and Gaussian estimation is often used to 
calculate a p-value [31]. 
2.3 Sequence Kernel Association Test (SKAT) 
SKAT is a regression-based method that can be used for continuous (Eq. 
4) or dichotomous (Eq. 5) phenotypes. In this study, I use the logit model (Eq. 5) 
because I have case-control data (described in Section 3.1).  
𝑦𝑖 = 𝛼! + 𝜶′𝑿𝒊 + 𝜷′𝑮𝒊 + 𝜀𝑖  Eq. 4 
𝑙𝑜𝑔𝑖𝑡  𝑃 𝑦𝑖 = 1 = 𝛼! + 𝜶′𝑿𝒊 + 𝜷′𝑮𝒊  Eq. 5 
Where, 
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𝑮𝒊: Vector of variants genotypes for individual 𝑖. Each entry of this 
vector can be 0, 1, or 2  
 𝒚𝒊: Phenotype for individual 𝑖 
𝑿𝒊  : Vector of covariates for individual 𝑖 
To test whether a certain genotype can be associated with a specific 
phenotype I test the null hypothesis 𝐻!:  𝜷 =  . If I assume each 𝛽 follows a 
random distribution with mean zero and variance 𝑤𝜏 (𝑤 is a pre-specified weight 
and 𝜏 is the variance component) then an equivalent statement for the null 
hypothesis is 𝐻!:    𝜏 = 0.  SKAT tests the latter form of null hypothesis and uses 
variance component score method to increase the power of the analysis of rare 
variants [32]. 
The statistic for the variance component score test is 𝑸 =(𝒚  –   𝝁)′𝑲(𝒚  –   𝝁), where 𝛍 is the mean of 𝒚 under the null hypothesis. 𝑲 
(𝑲 = 𝑮𝑾𝑮′) is called the kernel matrix where each entry is a measure of 
similarity between two individuals. 𝑮 is the genotype matrix and the (𝑖, 𝑗)th entry, 
𝑮𝒊𝒋, is the genotype data for the individual 𝑖 and variant 𝑗. 𝑾 is a diagonal matrix 
where 𝑤𝑗 entries represent a pre-specified weight for variant 𝑗. By choosing a 
larger 𝑤𝑗, I can up-weight causal variants, while a smaller 𝑤𝑗 down-weights non-
causal variants. But since I do not know which variants are causal and which are 
non-causal, SKAT estimates the weights based on the MAF for each variant [32]: 
𝑤𝑗 = 𝐵𝑒𝑡𝑎(𝑀𝐴𝐹𝑗; 𝑎!, 𝑎!)  Eq. 6 
  14 
The Beta distribution parameters are pre-specified based on how much I want to 
up-weight rare variants. For example 𝑎! = 𝑎! = 0.5 puts almost zero weights on 
variants with MAF larger that 1%. The default weights that SKAT suggests is 
𝑎! = 1  and  𝑎! = 25, since it puts decent weights for variants with MAFs=1-5% 
while up-weighting rare variants. The following figures show that how different 
beta distributions assigns weights based on a variant’s MAF. 
 
 
Figure 1: Beta(MAF; 0.3, 0.7) 
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Figure 2: Beta(MAF; 0.3, 0.9) 
 
 
Figure 3: Beta(MAF; 0.5, 0.5) 
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Figure 4: Beta(MAF; 1, 25) 
 
 
2.4 Single Variant Method (SVM) 
In this section, a new method for analyzing sequencing data is introduced. 
The main idea behind this method is that, it places its primary focus on variants 
whose frequencies differ between cases and controls. This difference is based 
on the mean of the minor allele counts in cases versus controls. In order to 
separate these variants from unimportant variants, I start with the following test: 
𝑆𝑐𝑜𝑟𝑒𝑇𝑒𝑠𝑡𝐴 𝑖 = 𝑚𝑒𝑎𝑛𝑐𝑎𝑠𝑒𝑠 𝑖 − 𝑚𝑒𝑎𝑛𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  Eq. 7 
Where, meancases(i)- represents the average number of minor alleles in 
cases for variant(i) and meancontrols(i) represents the average number of minor 
alleles in controls for variant(i). Later in this section I will expand the test from a 
single variant (i) to multiple variants in a gene (or pathway). 
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Before introducing the new test, I present and discuss a few examples. In 
the following example, where I calculate a score for a single locus, I assume that 
there are 8 cases and 8 controls. The number of minor alleles at a locus within 
an individual can take on discrete values of 0, 1, and 2 as described below: 
0: no minor allele exists at the ith locus in the jth individual 
1: only one minor allele exists at the ith locus in the jth individual 
2: two minor allele exist at the ith locus in the jth individual 
Example 1- In this example, I compare three different variants, as shown 
in Table 1. The first one, Var1, represents an extreme variant, in which all of the 
cases have one minor allele and all of the controls have zero minor alleles. For 
this variant, the mean number of minor alleles in cases is 
(1+1+1+1+1+1+1+1)/8=1, the mean number of minor alleles in controls is 
(0+0+0+0+0+0+0+0)/8=0, and their difference, i.e. 𝑆𝑐𝑜𝑟𝑒𝑇𝑒𝑠𝑡𝐴, is 1-0=1. An 
effective test should be able to identify this variant by producing a large value for 
𝑆𝑐𝑜𝑟𝑒𝑇𝑒𝑠𝑡𝐴, since there are many minor alleles in cases but none in control.  
Now let’s compare the first, Var1, and second, Var2, variants. In Var2, six 
out of eight cases has one minor allele but only three out of eight controls have 
one minor allele. For Var2, the mean number of minor alleles in cases is 
(1+1+1+1+1+0+0+1)/8=0.75 and the mean number of minor alleles in controls is 
(1+1+0+1+0+0+0+0)/8=0.375. Therefore, 𝑆𝑐𝑜𝑟𝑒𝑇𝑒𝑠𝑡𝐴 =  0.75-0.375=0.375. This 
value is smaller than the 𝑆𝑐𝑜𝑟𝑒𝑇𝑒𝑠𝑡𝐴 for Var1. Using this simple logic (which will be 
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modified below), this means Var1 is more likely to be associated with disease 
compared to Var2. 





Var1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 1 0 1 
Var2 1 1 1 1 1 0 0 1 1 0 1 0 1 0 0 0 0.75 0.375 0.375 
Var3 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0.375 0 0.375 
 
Table 1: Example 1, calculated scores for three variants based on TestA 
 
Next I compare the second, Var2, and third, Var3, variants. In Var3, three 
out of eight cases has one minor allele but none of controls have a minor allele. 
For Var3, the mean number of minor alleles in cases is 
(1+1+0+0+1+0+0+1)/8=0.375, the mean number of minor alleles in controls is 
(0+0+0+0+0+0+0+0)/8=0., and 𝑆𝑐𝑜𝑟𝑒𝑇𝑒𝑠𝑡𝐴=0.375-0=0.375. 
This value is the same as that for Var2. Since these scores are identical, 
TestA implies that both variants have the same probability in causing the disease.  
Unfortunately, this result does not make intuitive sense. Based on the data 
shown in Table 1, the probability that Var3 caused the disease should be higher 
than the probability that Var2 caused the disease. This is because, in Var3, none 
of the controls had minor alleles but 37.5% of cases had one minor allele. Based 
on this discussion, I need to define a more effective test that gives a higher score 
to Var3 compare to Var2. This can be achieved by considering the effect of 
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variations in the number of minor alleles in controls. Since the variation of 
number of alleles in controls inVar2 is higher than that of Var3, the probability that 
Var3 causes the disease should be higher. In order to increase the score of Var3, 
I define a new score, called 𝑆𝑐𝑜𝑟𝑒𝑇𝑒𝑠𝑡𝐵, by the following equation: 
𝑆𝑐𝑜𝑟𝑒𝑇𝑒𝑠𝑡𝐵 𝑖 = 𝑚𝑒𝑎𝑛𝑐𝑎𝑠𝑒𝑠 𝑖 − 𝑚𝑒𝑎𝑛𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 × !𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 !𝐶 =
𝑆𝑐𝑜𝑟𝑒𝑇𝑒𝑠𝑡𝐴 𝑖
!
𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 !𝐶  Eq. 8 
Where,  
• 𝑚𝑒𝑎𝑛𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 : average number of minor alleles in controls for variant (i) 
• 𝑚𝑒𝑎𝑛𝑐𝑎𝑠𝑒𝑠 𝑖 : average number of minor alleles in cases for variant (i) 
• 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 : standard deviation of the number of minor alleles in controls 
for variant (i)  
• 𝑆𝑐𝑜𝑟𝑒𝑇𝑒𝑠𝑡𝐵 𝑖 : score of TestB for variant (i)  
• C: a constant  
The new test, TestB, increases the weight of variants that have small variation in 
the number of alleles in controls by dividing the value of TestB by the standard 
deviation of the number of minor alleles in controls, 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 . Since 
𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  can be zero for some variants making the value of TestB infinite, I 
have added a constant, C, to the denominator to resolve this issue. For a very 
large constant, 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 ≪ 𝐶, the effect of 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  becomes negligible and 
scores of TestA and TestB become equal. For a very small constant, 
𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 ≫ 𝐶, the score of TestB, becomes a very strong function of 
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𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 . This significantly increases the score of variants with small 
𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 . Table 2 compares the scores of TestA and TestB for Var1, Var2, and 
Var3 for C=0.01. Tables 3 and 4 shows the score values for C=0.1 and C=1, 
respectively. 





Var1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 1 100 
Var2 1 1 1 1 1 0 0 1 1 0 1 0 1 0 0 0 0.5175 0.375 0.71 
Var3 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0.375 37.5 
Table 2-a: Comparison between TestA and TestB with constant C=0.01 
 




Var1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 1 100 
Var2 1 1 1 1 1 0 0 1 1 0 1 0 1 0 0 0 0.5175 0.375 24.7 
Var3 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0.375 37.5 
Table 2-b: Comparison between TestA and TestB with constant C=1 
 





Var1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 1 100 
Var2 1 1 1 1 1 0 0 1 1 0 1 0 1 0 0 0 0.5175 0.375 37.3 
Var3 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0.375 37.5 
Table 2-c: Comparison between TestA and TestB with constant C=100 
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In tables 2 to 4, the value of the standard deviation is calculated from the 
following equation: 
𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 = (𝑥𝑗!𝑚𝑒𝑎𝑛𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 )!𝑁𝑗!! 𝑁!!  Eq. 9 
In Eq. 9, N is the number of controls and 𝑥𝑗 is the number of minor alleles for 
control(j). As shown in tables 2 to 4, as the value of the constant, C, decreases 
the score of rare variant Var3, becomes much larger than that of Var2. This is 
because, for C=0.01, the denominator of Eq. 8 for Var2 is equal to 
𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 2 +C=0+0.01=0.01, which is a very small number. The denominator of 
Eq. 8 for Var3 is equal to 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 3 +C=0.5175+0.01=0.5275, which is much 
larger than 0.01. Based on this discussion, I conclude that the following 
coefficient can be used as a weighting factor for highlighting rare variants: 
𝑊𝑒𝑖𝑔ℎ𝑡 𝑖 = !
𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 !𝐶    Eq. 10 
In Figure 5, Weight is plotted as a function of 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  for constant 
values 0.001,0.01,0.03,0.1. As shown in this plot, for a very small value of the 
constant (e. g. 0.001), weight becomes a strong function of 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 . 
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Figure 5: Weight as a function of 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  for constant values 0.001, 0.01, 
0.03, 0.1 
 
2.4.1 Choosing a Proper Constant and Initial Results 
In this section, I explore the choice of a proper constant to analyze real 
sequence data in the setting of autism. Details of the origins of the autism data 
are shown in the next section. Since the constant, C, is added to 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  in 
the denominator, I need to examine the range of 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  in the autism 
dataset used here. This data set has 158,500 variants, 505 cases, and 491 
controls. In Figure 6, the histogram of 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  for all variants is shown.  
In the Autism dataset: 
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• 62,953 variants have 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 =0. This is because 62,953 variants have 
zero minor allele in the controls. We call these variants “category 0”. 
• 55,721 variants have 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 =0.0451. This is because 55,721 variants 
have only one minor allele in the controls. We call these variants “category 
1”. 
• 7,743 variants have 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 =0.0638. This is because 7,743 variants 
have only two minor alleles in all the controls. We call these variants 
“category 2”. 
• The remaining 32,083 variants have 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 >0.0775 
In the autism data set studied here, about 80% of variants are very rare in 
the sample of controls; the total count of the minor alleles in the controls is only 
0, 1, or 2 in these variants. Figure 7 shows the number of variants in each 
category. If we choose a constant that is much larger than the 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  for 
variants in categories 0, 1, and 2 (i.e. 𝐶 ≫ 0.0638) it will dominate the 
denominator in Eq. 8 and Eq. 10. This means that the score of the variant will 
mostly depend on the numerator of equation 8, which is (𝑚𝑒𝑎𝑛𝑐𝑎𝑠𝑒𝑠 𝑖 − 𝑚𝑒𝑎𝑛𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 ). On the other hand, if we choose a constant that is 
much smaller than the 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  for variants in categories 1 and 2 (i.e. 
𝐶 ≪ 0.0451) then the weight in Eq. 8 and 10 will be much larger for variants in 
category 0 than that of category 1. This very small constant will significantly 
increase the score of variants in category 0 by applying a large weight.  For these 
autism data, I decided to choose a constant equal to 0.03, which is between the 
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𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  of categories 0 and 1. These two categories account for about 75% 
of total variants.   
 
Figure 6: Histogram of 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  for all variants 
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Figure 7: Categorizing variants based on their total number of minor alleles in 
controls 
 
Using a constant of 0.03, the scores for all variants were calculated using 
TestB. These scores were ranked based on their absolute value. Table 5 shows 
the variants with the top 10 scores. In chapter 3, I discuss the presumed function 
of the genes identified by this analysis.  
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Variant ID Gene top 10 scores 
94857 OR4C3 -1.2541 
58551 PRIM2 -1.0068 
17318 OTOF 0.9900 
94855 OR4C3 -0.9240 
69095 TAS2R16 0.7260 
69096 TAS2R16 0.7260 
119078 C14orf80 0.7260 
224 CEP104 0.6600 
25659 DNAH7 0.6600 
43712 LEF1 0.6600 
Table 3: Variants with top 10 scores for constant C=0.03 
 
2.4.2 Estimating the P-values of the Measured Scores  
In order to calculate a p-value for each score, I randomly permuted the 
status of cases and controls 10,000 times. Each time a new score for the variant 
was calculated. In Figure 8, I plot the histogram of scores for 10,000 
permutations for variant ID=17318. This variant has the third largest score. The 
original score of this variant is shown with a red dot in Figure 8. As shown in this 
Figure, the original score is much larger than the scores calculated by 10,000 
permutations. If we assume a Gaussian distribution for the permuted scores, we 
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can estimate the p-value of the original score. The calculated p-value in Figure 8 
is equivalent to p-value of x=16.6 in standard normal distribution. This value is 
smaller than 10-300.  
 
Figure 8: Calculated scores for variant ID=17318, score=0.99 
 
Figure 9 shows the permutated scores for variant ID=224. The rank of this 
variant is 8. As shown in this figure, the original score (red dot) is much larger 
than that of permutated scores. The calculated p-value in Figure 9 is equivalent 
to P-value of x=11.7 in standard normal distribution. This value is smaller than 
10-300 also. 
Figure 10 shows the permutated scores for a low-ranking variant. As 
Figure 10 shows, the original score falls within the distribution of the permuted 
scores, and the estimated p-value is 0.03.  
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Figure 9: Calculated scores for variant ID=224, score=0.66 
 
 
Figure 10: Calculated scores for a low-rank variant 
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2.4.3 The Effect of Constant on the Score of Rare Variants 
In this section, I study the distribution of scores for different values of the 
constant C. Figure 11 and 12 show the sorted scores for all 158,500 variants 
calculated with constants C=0.001, 0.01, 0.03, 0.1. Based on these figures, the 
sorted scores show a discrete behavior. This is because many of the rare 
variants have exactly zero minor alleles in controls, which results in 
𝑚𝑒𝑎𝑛𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 = 0 and 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 = 0. For these variants, the score of TestB is 
determined by 𝑚𝑒𝑎𝑛𝑐𝑎𝑠𝑒𝑠 𝑖 . Since many of these variants have same value of 
𝑚𝑒𝑎𝑛𝑐𝑎𝑠𝑒𝑠 𝑖 , they cause horizontal lines in Figures 11 and 12. 
 
𝑆𝑐𝑜𝑟𝑒𝑇𝑒𝑠𝑡𝐵 𝑖 = (𝑚𝑒𝑎𝑛𝑐𝑎𝑠𝑒𝑠 𝑖 − 𝑚𝑒𝑎𝑛𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 ) !𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 !𝐶 =(𝑚𝑒𝑎𝑛𝑐𝑎𝑠𝑒𝑠 𝑖 − 0) !!!𝐶 = 𝑚𝑒𝑎𝑛𝑐𝑎𝑠𝑒𝑠 𝑖𝐶     Eq. 11 
 
Figure 11: Calculated scores for multiple constants 
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Figure 12: Calculated scores for multiple constants. Zoomed version 
 
In order to study the effect of the score on the rank of rare variants, I have 
listed 10 variants with largest positive scores as well as top-10 variants with 
negative scores. These variants are sorted in Table 4 based on the absolute 
value of their scores for constants C=0.001, 0.01, and 0.03. As shown in this 
table, by increasing the constant, the rank of variants changes. For example, the 
rank of variant ID=94855 is 2, 2, 3 for constants 0.001, 0.01, and 0.03 
respectively. Note that for C=0.001, 0.01, and 0.03, the ranks of variants with 10 
largest positive scores do not change. Also note that by increasing the constant 
C from 0.001 to 0.01, the ranks of variants with largest 8 negative scores do not 
change, but the ones with ranks 9 and 10 do change. By increasing the constant 
from C=0.01 to C=0.03, the rank of variant ID=58551 changes from 9 to 2. In 
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addition, two new variants with IDs=94856, 33571 appear in the top-10 list of 
variants with negative scores.   
One of the challenging tasks in this work is to find a proper constant. I 
argue that since the constant C is added with 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖   in the denominator of 
the score it should not be much larger or much smaller than the 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖  of 
most of the variants. Since 62,953/158,500=39.7% of the variants have 
𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 = 0, 55,721/158,500=35.2% have 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 = 0.0451, and 
7,743/158,500=4.9% have 𝑆𝐷𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑖 = 0.0638, C=0.03 appears to be a better 
choice than C=0.01 or C=0.001. 
C=0.001 C=0.01 C=0.03 C=0.001 C=0.01 C=0.03 
Variant ID Variant ID Variant ID top 10 positive 
scores  
top 10 positive 
scores 
top 10 positive 
scores 
17318      17318      17318      2.9703*10      2.9703 0.9900 
69095 69095 69095 2.1782*10      2.1782 0.7260 
69096 69096 69096 2.1782*10  2.1782 0.7260 
119078 119078 119078 2.1782*10      2.1782 0.7260 
224 224 224 1.9802*10      1.9802 0.6600 
25659 25659 25659 1.9802*10      1.9802 0.6600 
43712 43712 43712 1.9802*10      1.9802 0.6600 
60198 60198 60198 1.9802*10      1.9802 0.6600 
74681 74681 74681 1.9802*10      1.9802 0.6600 
92982 92982 92982 1.9802*10      1.9802 0.6600 
********* ********* ********* top 10 negative 
scores 
top 10 negative 
scores 
top 10 negative 
scores 
94857 94857 94857 -3.7624*10      -3.7624 -1.2541 
94855 94855 58551 -2.7723*10        -2.7723   -1.0068 
802 802 94855 -1.9802*10        -1.9802   -0.9240 
118936 118936 802 -1.7822*10        -1.7822   -0.6600 
98240 98240 94856 -1.5842*10        -1.5842   -0.6288 
34838 34838 118936 -1.3861*10        -1.3861   -0.5940 
122967 122967 98240 -1.3861*10        -1.3861   -0.5280 
122973 122973 33571 -1.3861*10        -1.3861   -0.4651 
1859 58551 34838 -1.1881*10        -1.2356 -0.4620 
90187 1859 122967 -1.1881*10        -1.1881   -0.4620 
Table 4: Calculated scores for multiple constants 
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To further study the effect of the constant, I calculated both the p-values 
and the scores for the variants that appeared in the above top-10 list. Some of 
these variants appeared for multiple constants and some of them appeared for 
only one constant. The ID number of these variants are 94857, 58551, 17318, 
94855, 69095, 69096, 119078, 224, 25659, 43712, 60198, 74681, 92982, 802, 
94856, 118936, 98240, 33571, 34838, 122967, 122973, 7991, 77556, 33576, 
96949, 95837, 1859, 90187, 90225, 120974, 94889, 95118, 1763, 134370, 5016, 
133174, 58524. This is performed for C=0.001, 0.01, 0.02, 0.03, 0.06 and 0.08. 
In addition to the above-mentioned high-rank variants, I randomly selected and 
added two variants to the list. The IDs of these two variants are 1000 and 5000. 
Their ranks for C=0.03 are 16993 and 9349, and their scores are 0.066 and 
0.115, respectively. The scores and the p-values are listed in Tables 5 and 6. 
The variants in Tables 5 and 6 are sorted based on the absolute value of their 
scores calculated with C=0.03. In Table 6, p-values smaller than 10-230 are shown 
by 0. Based on these two tables, I conclude that the results do not change much 
by varying the constant from 0.001 to 0.03. Further, p-values for all high-rank 
variants are much smaller than the p-values of the two insignificant variants (IDs 
1000 and 5000). 
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 Variant ID C=0.001 C=0.01 C=0.02 C=0.03 C=0.06 C=0.08 
1 94857 -3.8E+01 -3.8E+00 -1.9E+00 -1.3E+00 -6.3E-01 -4.7E-01 
2 58551 -1.4E+00 -1.2E+00 -1.1E+00 -1.0E+00 -7.9E-01 -6.9E-01 
3 17318 3.0E+01 3.0E+00 1.5E+00 9.9E-01 5.0E-01 3.7E-01 
4 94855 -2.8E+01 -2.8E+00 -1.4E+00 -9.2E-01 -4.6E-01 -3.5E-01 
5 69095 2.2E+01 2.2E+00 1.1E+00 7.3E-01 3.6E-01 2.7E-01 
6 69096 2.2E+01 2.2E+00 1.1E+00 7.3E-01 3.6E-01 2.7E-01 
7 119078 2.2E+01 2.2E+00 1.1E+00 7.3E-01 3.6E-01 2.7E-01 
8 224 2.0E+01 2.0E+00 9.9E-01 6.6E-01 3.3E-01 2.5E-01 
9 25659 2.0E+01 2.0E+00 9.9E-01 6.6E-01 3.3E-01 2.5E-01 
10 43712 2.0E+01 2.0E+00 9.9E-01 6.6E-01 3.3E-01 2.5E-01 
11 60198 2.0E+01 2.0E+00 9.9E-01 6.6E-01 3.3E-01 2.5E-01 
12 74681 2.0E+01 2.0E+00 9.9E-01 6.6E-01 3.3E-01 2.5E-01 
13 92982 2.0E+01 2.0E+00 9.9E-01 6.6E-01 3.3E-01 2.5E-01 
14 802 -2.0E+01 -2.0E+00 -9.9E-01 -6.6E-01 -3.3E-01 -2.5E-01 
15 94856 -7.7E-01 -7.2E-01 -6.7E-01 -6.3E-01 -5.3E-01 -4.8E-01 
16 118936 -1.8E+01 -1.8E+00 -8.9E-01 -5.9E-01 -3.0E-01 -2.2E-01 
17 98240 -1.6E+01 -1.6E+00 -7.9E-01 -5.3E-01 -2.6E-01 -2.0E-01 
18 33571 -5.2E-01 -5.0E-01 -4.8E-01 -4.7E-01 -4.2E-01 -3.9E-01 
19 34838 -1.4E+01 -1.4E+00 -6.9E-01 -4.6E-01 -2.3E-01 -1.7E-01 
20 122967 -1.4E+01 -1.4E+00 -6.9E-01 -4.6E-01 -2.3E-01 -1.7E-01 
21 122973 -1.4E+01 -1.4E+00 -6.9E-01 -4.6E-01 -2.3E-01 -1.7E-01 
22 7991 -5.2E-01 -5.0E-01 -4.8E-01 -4.6E-01 -4.1E-01 -3.9E-01 
23 77556 6.1E-01 5.4E-01 4.7E-01 4.2E-01 3.2E-01 2.7E-01 
24 33576 -4.7E-01 -4.5E-01 -4.3E-01 -4.1E-01 -3.6E-01 -3.4E-01 
25 96949 -5.5E-01 -4.9E-01 -4.4E-01 -4.0E-01 -3.1E-01 -2.7E-01 
26 95837 5.8E-01 5.1E-01 4.5E-01 4.0E-01 3.0E-01 2.6E-01 
27 1859 -1.2E+01 -1.2E+00 -5.9E-01 -4.0E-01 -2.0E-01 -1.5E-01 
28 90187 -1.2E+01 -1.2E+00 -5.9E-01 -4.0E-01 -2.0E-01 -1.5E-01 
29 90225 4.2E-01 4.1E-01 4.0E-01 3.9E-01 3.7E-01 3.5E-01 
30 120974 4.8E-01 4.3E-01 3.9E-01 3.6E-01 2.9E-01 2.5E-01 
31 94889 -3.4E-01 -3.3E-01 -3.2E-01 -3.1E-01 -2.9E-01 -2.7E-01 
32 95118 3.4E-01 3.3E-01 3.2E-01 3.1E-01 2.9E-01 2.7E-01 
33 1763 3.5E-01 3.3E-01 3.2E-01 3.0E-01 2.6E-01 2.4E-01 
34 134370 3.1E-01 3.0E-01 2.9E-01 2.8E-01 2.6E-01 2.4E-01 
35 5016 -2.7E-01 -2.7E-01 -2.7E-01 -2.6E-01 -2.5E-01 -2.5E-01 
36 133174 2.8E-01 2.7E-01 2.7E-01 2.6E-01 2.4E-01 2.3E-01 
37 58524 2.6E-01 2.6E-01 2.5E-01 2.5E-01 2.4E-01 2.3E-01 
38 5000 -1.2E-01 -1.2E-01 -1.2E-01 -1.2E-01 -1.1E-01 -1.1E-01 
39 1000 2.0E+00 2.0E-01 9.9E-02 6.6E-02 3.3E-02 2.5E-02 
 
Table 5: Scores for variants calculated for C=0.001, 0.01, 0.02, 0.03, 0.06, 0.08 
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 Variant ID C=0.001 C=0.01 C=0.02 C=0.03 C=0.06 C=0.08 
1 94857 0.0E+00 0.0E+00 2.7E-223 2.1E-117 3.7E-43 3.3E-29 
2 58551 1.6E-98 2.2E-86 1.2E-77 4.1E-68 5.8E-53 3.5E-45 
3 17318 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 
4 94855 0.0E+00 0.0E+00 9.1E-121 1.5E-65 1.1E-24 3.0E-18 
5 69095 0.0E+00 0.0E+00 0.0E+00 0.0E+00 4.2E-15 3.7E-11 
6 69096 0.0E+00 0.0E+00 0.0E+00 0.0E+00 4.2E-15 3.7E-11 
7 119078 0.0E+00 0.0E+00 0.0E+00 0.0E+00 1.0E-12 5.6E-10 
8 224 0.0E+00 0.0E+00 0.0E+00 0.0E+00 6.0E-12 9.2E-10 
9 25659 0.0E+00 0.0E+00 0.0E+00 0.0E+00 1.2E-14 7.7E-11 
10 43712 0.0E+00 0.0E+00 0.0E+00 0.0E+00 5.1E-14 6.0E-11 
11 60198 0.0E+00 0.0E+00 0.0E+00 0.0E+00 2.6E-14 3.6E-11 
12 74681 0.0E+00 0.0E+00 0.0E+00 0.0E+00 3.6E-14 6.2E-11 
13 92982 0.0E+00 0.0E+00 0.0E+00 0.0E+00 4.6E-14 5.1E-11 
14 802 3.4E-100 3.2E-77 1.3E-32 9.3E-23 1.0E-11 1.8E-09 
15 94856 8.3E-33 4.2E-31 3.6E-29 3.8E-28 2.1E-24 8.3E-23 
16 118936 9.8E-72 4.4E-39 8.7E-24 2.4E-17 6.0E-10 4.5E-08 
17 98240 1.9E-44 2.7E-40 2.2E-21 9.2E-17 3.1E-09 5.2E-08 
18 33571 2.4E-16 7.1E-16 1.2E-15 1.7E-15 5.3E-15 1.9E-14 
19 34838 9.1E-13 9.8E-13 7.1E-11 8.2E-09 4.6E-06 3.4E-05 
20 122967 7.4E-15 3.6E-14 1.3E-11 5.3E-09 4.5E-06 4.4E-05 
21 122973 7.4E-15 3.6E-14 1.3E-11 5.3E-09 4.5E-06 4.4E-05 
22 7991 1.6E-16 3.0E-16 5.0E-16 1.7E-15 8.7E-15 1.9E-14 
23 77556 0.0E+00 7.8E-16 2.0E-14 3.4E-13 7.9E-11 5.8E-10 
24 33576 1.0E-13 3.0E-13 7.7E-13 8.1E-13 4.2E-12 6.1E-12 
25 96949 1.4E-15 1.3E-13 1.2E-12 7.3E-12 4.8E-10 1.1E-09 
26 95837 0.0E+00 6.7E-16 2.1E-14 5.2E-13 1.0E-10 7.1E-10 
27 1859 1.0E-04 1.4E-04 1.5E-04 4.9E-04 1.3E-03 2.5E-03 
28 90187 8.9E-15 7.8E-13 5.5E-11 2.2E-08 3.7E-06 2.9E-05 
29 90225 1.6E-11 1.5E-11 1.3E-11 1.9E-11 2.5E-11 3.5E-11 
30 120974 7.2E-12 1.6E-10 3.7E-10 1.8E-09 2.2E-08 9.6E-08 
31 94889 4.3E-08 3.9E-08 6.1E-08 6.0E-08 8.2E-08 8.2E-08 
32 95118 4.7E-08 4.5E-08 7.3E-08 9.3E-08 1.0E-07 1.1E-07 
33 1763 4.7E-08 3.8E-08 8.4E-08 8.0E-08 1.9E-07 2.7E-07 
34 134370 6.2E-07 7.3E-07 7.4E-07 1.0E-06 1.3E-06 1.1E-06 
35 5016 8.1E-06 1.0E-05 7.2E-06 7.7E-06 1.0E-05 7.6E-06 
36 133174 5.4E-06 6.1E-06 7.2E-06 8.8E-06 7.7E-06 8.0E-06 
37 58524 1.9E-05 1.9E-05 1.4E-05 1.5E-05 1.4E-05 1.5E-05 
38 5000 2.7E-02 2.7E-02 2.7E-02 2.8E-02 2.7E-02 2.7E-02 
39 1000 1.6E-01 1.6E-01 1.6E-01 1.6E-01 1.6E-01 1.6E-01 
Table 6: P-values for variants calculated for C=0.001, 0.01, 0.02, 0.03, 0.06, 0.08 
 
2.4.4 Calculating the Score of Genes based on the Score of Variants 
In this section, I introduce a method for calculating the score of genes.  In 
order to calculate this score, the following equation will be used: 
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𝐺𝑒𝑛𝑒_𝑆𝑐𝑜𝑟𝑒 = 𝑆𝑐𝑜𝑟𝑒𝑇𝑒𝑠𝑡𝐵(𝑖)𝑁𝑖!!
𝑁
 Eq. 12 
In equation 12, the mean of the absolute values of the scores of variants 
in each gene is calculated, where N is equal to the number of variants in the 
gene. If a gene contains variants with very high Variant_score, the Gene_score 
will also be large. In Chapter 3, the genes with 100 highest scores are reported. 





CHAPTER III: AUTISM SPECTRUM DISORDER DATA 




3.1 Autism Spectrum Disorder Data 
In this study, I have analyzed exome sequencing data from 505 autism 
cases (440 males, 65 females), and 491 controls (240 males, 251 females). A 
case was defined using standard tests: Autism Diagnostic Interview-Revised 
(ADI-R), and Autism Diagnostic Observation Schedule-Generic (ADOS). These 
tests examine the child for autism symptoms such as repetitive and stereotype 
behaviors, social communication, language proficiency, and intellectual ability. All 
cases met the criteria for Autism Spectrum Disorder. The controls data was 
obtained from the NIMH repository such that they have similar ancestry to cases. 
NIMH repository has produced the controls data from the cord blood samples of 
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a group of Caucasian people, and a group of individuals who completed a short 
self-report clinical assessment [44]. Written informal consent was obtained from 
all study participants. 
The sequence data were generated by the Human Genome Sequencing 
Center at Baylor College of Medicine using the Solid sequencing platform (Life 
Technologies, Carlsbad, CA). Exons were captured using NimbleGen VCRome 
2.1 and the average depth of data coverage is 80% at 20X. To process the data, 
Picard (http://picard.sourceforge.net/) was used to map the data to hg19 using 
base quality score recalibration, and BWA was used to realign the data at certain 
indels [40]. GATK [41,42] was used for calling bases and the variable that did not 
pass GATK standard filters were excluded from our data. For annotating the 
variants RefSeq hg19 was used.  
3.2 Results 
In Table 7, I report the 100 most significant genes that are identified based 
on SKAT 𝑎! = 𝑎! = 0.5 , SKAT 𝑎! = 1, 𝑎! = 25 , WSM(permutations=10k), 
SVM(Constant=0.001), and SVM(Constant=0.03). To find the 100 most 
significant genes in Table 7, I sorted the genes based on their p-values in 
ascending order in the first 3 columns  (for SKAT and WSM methods). Therefore 
the first gene (first rows for SKAT and WSM) has the smallest p-value. For SVM 
method (the last two columns), I sorted the genes based on their scores in 
descending order. The first gene (first row for SVM) has the largest score.  
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As discussed in the previous chapter, SKAT 𝑎! = 𝑎! = 0.5   assigns almost 
zero weights to variants with MAF larger than 1% and SKAT 𝑎! = 1, 𝑎! = 25  
assigns decent weights for variants with MAFs=1-5% while up-weighting rare 
variants [32]. I performed WSM method with 10k permutations to achieve 
accurate p-values. I also performed the gene-based SVM method (see section 
2.4.4) with two constants 0.001 and 0.03. Constant=0.001 assigns more weight 
to rare variants than constant=0.03.  
SKAT 𝒂𝟏  = 𝒂𝟐  =  𝟎.𝟓   SKAT 𝒂  = 𝟏 ,𝒂  =  𝟐𝟓   WSM(perm:10k) SVM(C=0.001) SVM(C=0.03) 
PNLIPRP2 KANK1 PNLIPRP2 HSD3B1 HSD3B1 
STAB2 KIR3DL3 ATP1A1 MRPS11 MRPS11 
AGXT2L1 RLBP1 YTHDC2 C14orf80 C14orf80 
PRIM2 SLC28A1 KRT75 APH1A APH1A 
RLBP1 APPBP2 EFR3B RTN4IP1 RTN4IP1 
SRGN CLDN12 C1orf51 RPL3 RPL3 
SPINLW1-WFDC6 CUBN ALOX5 TMEM82 OR10G8 
EIF4G3 ZNF518B TWF2 MSGN1 TAS2R16 
INADL BEST1 MYH15 ETV2 TMEM82 
KANK1 OPN1SW CCDC42 TAS2R16 MSGN1 
APPBP2 EPHB2 EYA2 GPX2 ETV2 
SLC24A5 EIF4G3 CENPW PAQR7 GPX2 
SLC39A14 SPINLW1-WFDC6 EFCAB4B MRPL46 MRPL46 
CLDN12 PAX4 SPRR3 STMN1 PAQR7 
OR4C45 TTLL11 C4orf22 AHSA2 GPR152 
EFCAB4B SMARCD3 TTLL11 LY75 C11orf31 
EFR3B ALX4 FANK1 ATP5J2 STMN1 
OPN1SW STAB2 PSMD1 GPR135 AHSA2 
ZNF217 SLC24A5 CDAN1 PLIN5 LY75 
ZNF518B AGXT2L1 SLC38A4 PDCD5 ATP5J2 
EPHB2 ZNF217 ZFP106 KRTAP6-3 GPR135 
SPRR3 SLC39A14 HOMER3 ISPD PLIN5 
BACH1 BBS4 SLC39A14 CYBA PDCD5 
SMARCD3 DDO RNF216 ZCCHC7 KRTAP6-3 
STRA6 IFI35 DENND1B LDHC ISPD 
UGGT1 OR6M1 EPC1 BTN3A2 CYBA 
CUX1 MDGA2 XIRP1 OR4N5 C17orf58 
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TTLL11 NIPAL4 ZZEF1 PCBP4 BTN3A2 
ARID1A PARP15 RABL5 APOBEC3F ZCCHC7 
OR5B12 LRRC23 LRRC71 OR2AE1 LDHC 
FRMD3 TET2 GPRIN1 KLHL17 OR2AE1 
GPLD1 BUB1B ATP13A2 ST6GAL1 NFYB 
TTC15 GPR152 HSPBAP1 C9orf153 KRT32 
BBS4 KRTAP26-1 GALNTL2 FES OR4N5 
NIPAL4 GRLF1 C14orf80 CD33 PCBP4 
GPR152 PRDM16 OR5AU1 OR6V1 APOBEC3F 
YTHDC2 FRMD3 CAPN10 KRT32 HCRTR1 
CSRNP3 WNK1 TMPO HCRTR1 KLHL17 
DENND1B CPOX ZNF233 IL6ST ST6GAL1 
TET2 FAM134A CLCN1 SPATA7 OR6V1 
ACO1 C17orf64 RRH LRRC19 ONECUT2 
CTNNA3 OR51E2 GPR87 CETN1 BBC3 
CCDC11 FBXO4 CST7 PCP4L1 OR4C3 
GRIP1 THAP7 ATG4B TMEM86A CUEDC1 
CUBN C14orf80 CAPZA3 NMU C9orf153 
THAP7 CCDC11 SPATS2L MRPL27 FES 
ALX4 WNT2B C12orf65 AKAP5 CHAC1 
ADAR CIT 8-Sep CCDC90A KRTAP19-8 
DOK6 ST5 SPARC KLHDC7A CD33 
PFKFB2 CNTLN TAT AKIRIN1 PARP15 
PARP15 RPRD2 ERRFI1 S100A2 IL6ST 
IFI35 ATAD2 POLD1 LENEP PRDX3 
CENPW KRTAP19-8 GPR152 LBH CETN1 
HOXB2 SIM1 MFI2 ACTG2 SKA1 
TAS2R16 ABCG2 ORM2 IL36RN MEOX2 
OR51A7 GPLD1 APAF1 SMPD4 KCTD6 
HRASLS5 C20orf85 TRPM2 PHOSPHO2 PCP4L1 
ZCCHC4 DNAJB12 DIXDC1 GLS SPATA7 
KRTAP19-8 ZRANB3 BPTF TMEM115 LRRC19 
C14orf80 VPS33B CYP27A1 COL8A1 HSPB8 
ARFGAP2 RASGEF1C AMHR2 IGF2BP2 ZCCHC4 
ZNF717 GPRIN1 POLA2 PAQR3 SNX15 
FBXO4 PRKG1 SLC25A44 IL21 TMEM86A 
CIT ERLEC1 LDHC TAF7 POLD1 
C20orf26 SRGN SMC3 ZNF354A SPP1 
XPO1 ACO1 KIAA1199 TTYH3 NMU 




CYBA ARID1A BTAF1 RBAK TLR2 
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GPRIN1 CYBA AURKC PHKG1 FGF6 
SIM1 FCHO2 COMT GNGT1 MRPL27 
KRT75 VSIG10L CACNA2D4 MRPS33 CRNN 
CRNN SNX27 ABHD12 NDUFB6 CENPW 
WBP4 ATP1A1 TMEM207 CTSL1 AKAP5 
MARK1 TTC15 HTR4 C9orf9 CCDC90A 
KLHL35 OR51A7 GPN2 CREM KLHDC7A 
MEGF8 CYP27A1 PEAR1 DKK1 AKIRIN1 
DNAJB12 MYBPH FES MINPP1 S100A2 
SPOCD1 FABP9 ODZ4 APIP LENEP 
LRRC71 ZNF214 STAB2 CD248 LBH 
CDAN1 PLSCR4 MTERF SSH3 ACTG2 
DNAH7 HOXB2 AP1G1 CCND2 IL36RN 
C1orf135 IL6ST ANKFN1 COMMD6 SMPD4 
GSN CTNNA1 PLA2G1B C14orf119 PHOSPHO2 
BUB1B ST6GAL1 AGBL1 ISLR GLS 
RAD52 OR5B12 COG2 UNKL TMEM115 
SHISA6 XPO1 SDF4 APOBR COL8A1 
OR6T1 KLHL35 FBN1 ZNF771 IGF2BP2 
OR4D5 BOD1 OTOGL PSMD7 PAQR3 
ZHX1-C8ORF76 KDM5A HORMAD2 KCNJ2 IL21 
RPTN AMHR2 PEX7 UQCR11 TAF7 
SLC27A6 SPOCD1 EPHB2 DNAJB1 ZNF354A 
MYPN KIAA1751 ATAD2 MED26 TTYH3 
MYBPH WBP4 STXBP1 TPRX1 
RBAK-
LOC389458 
ST5 BACH1 FAM190B MYL9 RBAK 
CTNNA1 OR6T1 MYBPH BIRC7 PHKG1 
ABCG2 GSN TTC39B TPD52L2 GNGT1 
KRTAP26-1 TACR2 SYNGR4 LMF2 MRPS33 
BTNL8 TAS2R16 IFNE PARP15 NDUFB6 
OR4K1 0.003209799 TMEM44 ZCCHC4 CTSL1 
IFIH1 0.003224207 C15orf33 ABCG4 C9orf9 
Table 7: 100 most significant genes identified with different methods 
3.3 Discussion 
Based on the results reported in Table 7, I found that the gene C14orf80 is 
the only gene that is common among all methods. The rank of this gene using 
methods SKAT(0.5,0.5), SKAT(1,25), WSM(10k), SVM(0.001),  SVM(0.03) is 60, 
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45, 35, 3 and 3, respectively. This gene is shown in color ☐ in Table 7. The fact 
that the proposed method (SVM) calculates a high rank for this gene confirms the 
effectiveness of the SVM method and the robustness of this result. 
The second category of seemingly important genes is the genes that exist 
in 4 (out of 5) methods. I found that the gene GPR152 was detected by 
SKAT(0.5,0.5), SKAT(1,25), WSM(10k), SVM(0.03), but not in SVM(0.001). The 
rank of this gene by these methods is 36, 33, 53, 15, respectively. This gene is 
shown in color ☐ in Table 7. I found that the genes TAS2R16, CYBA, and 
PARP15 exist in methods SKAT(0.5,0.5), SKAT(1,25), SVM(0.001), SVM(0.03), 
but not in WSM(10k). The rank of gene TAS2R16 in these four methods is 55, 
98,10, 8, respectively. SVM (0.03) calculates a high rank for this gene. The rank 
of gene CYBA, in methods SKAT(0.5,0.5), SKAT(1,25), SVM(0.001),  SVM(0.03) 
is 68, 69, 23 and 26, respectively. SVM (0.03) calculates a high rank for this gene 
as well. The rank of gene PAR15 in SKAT(0.5,0.5), SKAT(1,25), SVM(0.001), 
SVM(0.03) is 51, 29, 98 and 50, respectively. Genes TAS2R16, CYBA and 
PARP15 are shown in color ☐ in Table 7. 
The biological function of the significant (colored) genes that I identified 
are listed below along with a hypothesized relationship to autism, when possible: 
C14orf80: codes for uncharacterized protein C14orf80. 
TAS2R16: codes for a bitterness taste receptors. Although TAS2R16 has 
not been associated with autism, TAS2R1, which has the same function 
(perception of bitterness) has been significantly associated with autism in 
previous studies [34,35]. Bennetto et al. [34] have reported that taste 
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perception in autistic children significantly differs than that of non-autistic 
children. In a case-control study by Baron-Cohen and Tavassoli, it is 
reported that the taste perception in adults with autism was significantly 
less accurate than that of controls [35]. 
GPR152: encodes for G Protein-Coupled Receptor PGR5, which is 
an Orphan receptor. (Source: http://www.genecards.org) 
CYBA: mutation in this gene is associated with granulomatous disease, 
which is an immune system disorder. (Source: 
http://www.genecards.org) 
PARP15: Functions as transcriptional repressor, which has ADP-
ribosyltransferase activity. (Source: http://www.genecards.org) 
3.4 Conclusions 
Based on the results reported on Table 7, one can see that the significant 
genes detected by different methods are not consistent. Since there is no gold 
standard, I cannot claim a particular method is the most accurate. One approach 
to identify novel genes in this field could be using multiple methods and finding 
significant genes that are common among these methods. 
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APPENDIX A: MATLAB CODES 
In this section, the MATLAB codes used for calculating the core of variants 
and genes are reported.  
Code-1: Calculating the scores of each variant using TestB 
clear;  
Description: This command clears the existing variables 
 
load GT_noXY;  
Description: This command loads the genotype matrix and stores it in GT_noXY 
 
[snp,ID]=size(GT_noXY); 
Description: This command calculates the number of variants and the total 
number of cases/controls that exist in the genotype matrix. The number of 
variants is stored in variable snp and the total number of cases/controls is stored 
in variable ID. 
 
data_case=GT_noXY(:,1:505); 
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Description: This commands defines a constant and stores it in constant C1. 
for k=1:snp 
Description: This command starts a loop. 
 
avg_case(k)=mean(GT_noXY(k,1:505)); 
Description: This command calculates the mean of minor alleles in cases for 
variant k.  
 
avg_control(k)=mean(GT_noXY(k,506:996)); 
Description: This command calculates the mean of minor alleles in controls for 
variant k.  
 
var_control(k)=var(GT_noXY(k,506:996)); 
Description: This command calculates the variance of minor alleles in controls for 
variant k.  
 
stat(:,k)=(GT_noXY(:,k)-avg_control(:))./(var_control(:)+C1); 
Description: This command calculates the score of each variant. 
 
end; 
Description: This command ends the loop. 
 
Code-2: Calculating the scores of each gene 
clear; 
Description: This command clears the existing variables 
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snp_loc=csvread('snp_location.csv'); 
Description: This command reads the location of each variant and stores it in 
variable snp_loc. 
 
save snp_loc snp_loc 
Description: This command saves the variable snp_loc 
 
gene_loc=csvread('gene_loc.csv'); 
Description: This command reads the start and stop of each gene and stores it in 
variable gene_loc. 
 
save gene_loc gene_loc 
Description: This command saves the variable gene_loc 
 
load GT_noXY; 
Description: This command loads the genotype matrix. 
 
data_case=GT_noXY(:,1:505); 








Description: This command starts a loop. 
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gene_score(k1)=0; 
Description: This command sets the score of gene K1 to zero.  
 
gene_len(k1)=0; 
Description: This command sets the length of gene K1 to zero.  
 
for k2=1:length(snp_loc) 
Description: This command starts a loop.  
 
if (gene_loc(k1,1)<=snp_loc(k2,1))&(snp_loc(k2,1)<=gene_loc(k1,2)) 





Description: If snp_loc(k2,1) belongs to gene K1, this command adds the score 
of variant K2 to gene K1.  
 
gene_len(k1)=gene_len(k1)+1; 
Description: If snp_loc(k2,1) belongs to gene K1, this command adds the value of 
variable gene_len by 1. 
 
end; 
This command closes the first loop. 
 
end; 
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This command closes the second loop. 
gene_score_norm=gene_score./gene_len; 
This command divides the score of each gene before normalization by the 
number of variants that exist in that gene. This variant is a vector that contains 
the scores of all genes.  
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